Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P56851 (
epididymal
)
11,273
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effects of
NS 1619
, a newly developed activator of large-conductance Ca2+-activated K+ channels, were investigated on single smooth muscle fibers dissociated enzymatically from rat vas deferens and on contractions of the
epididymal
half of vas deferens. K+ currents were recorded using whole-cell patch-clamp methods in near-physiological K+ solutions (5.4 mM extracellular K+/145 mM intracellular K+). When cell membrane voltage was stepped to test potentials (-60 to +60 mV) from a holding potential of -10 mV,
NS 1619
increased the outwardly rectifying K+ current in a concentration-dependent manner. The increased portion of the K+ current by
NS 1619
was totally abolished by charybdotoxin (100 nM) but not by glibenclamide (3 microM).
NS 1619
reduced electrically stimulated contractile responses of rat vas deferens in a concentration-dependent manner, and charybdotoxin but not glibenclamide partially inhibited the effect of
NS 1619
.
NS 1619
(50 microM) inhibited the noradrenaline-induced contraction. Charybdotoxin (100 nM) partially reduced the
NS 1619
-induced inhibition while glibenclamide (3 microM) had no effect.
NS 1619
(10-100 microM) reduced the high K+-induced contractions in a noncompetitive manner. The present results indicate that
NS 1619
activates charybdotoxin-sensitive Ca2+-activated K+ channels and probably inhibits Ca2+ influx. These two effects might account largely for the observed mechanical inhibition induced by
NS 1619
in the
epididymal
half of isolated rat vas deferens.
...
PMID:NS 1619 activates Ca2+-activated K+ currents in rat vas deferens. 915 34
